Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc.
Acquisition Will Enhance SAGE Labs' Rodent Husbandry Capabilities; Adds New Models to Product Portfolio and Strategic Location for Animal Distribution
PR Newswire
ST. LOUIS, March 16
ST. LOUIS, March 16 /PRNewswire-FirstCall/ --
Sigma-Aldrich® (Nasdaq: SIAL) today announced it has signed an agreement to acquire Ace Animals, Inc., a Berks County, PA.-based provider of high quality research rodents to the biomedical industry. Ace Animals (www.aceanimals.com), a commercial rodent breeder established in 1973, offers high quality products and contract breeding services, and will operate as part of Sigma Advanced Genetic Engineering (SAGE™) Labs (www.sageresearchmodels.com), a Sigma® Life Science initiative. Terms and conditions of the agreement were not disclosed. Closing is expected shortly.
The acquisition will enhance SAGE Labs' current rat and mouse breeding capabilities, primarily used in the development and characterization of its unique, next-generation 'Knockout' and 'Knockin' rat models featuring specific gene deletions, insertions, repressions and modifications created using proprietary CompoZr™ Zinc Finger Nuclease (ZFN) technology. In addition, Ace Animals' strategic location in Pennsylvania is expected to greatly enhance distribution of SAGE Labs models to key sites within the United States bio-pharma industry.
Through the acquisition, SAGE Labs plans to offer a significantly increased portfolio of products and services, including a number of 'wild type' (that is, animals that have not been genetically modified) rats and mice, including Swiss Webster, Sprague Dawley, ICR, Balb/c, C57BL/6 and Cotton Rats. SAGE Labs will be positioned to offer contract breeding services, considered a natural extension of its current SAGEspeed™ animal creation service. Concurrently, Ace Animals, Inc.'s customers are expected to benefit from access to the industry-leading genetic engineering platforms offered through Sigma's SAGE labs.
SAGE Labs is the premier resource for genetically modified rodent disease models and markets its exclusive SAGEspeed™ Custom Model Development program for the creation of knockout mouse or rat models in as little as five months. The group is also developing their catalog of knockout rat models across a number of research fields, including Neurobiology, Toxicology, Cardiology and Immunology.
"With the Ace Animals acquisition, SAGE Labs will be in a better position to offer a greater number of models with the goal of helping researchers understand the functional significance of genes and their relationships to human diseases," said Dr. Edward Weinstein, Director of SAGE Labs. "In vivo models of human disease states serve as more predictive proxies to the human condition, and therefore are instrumental to the discovery of novel and powerful therapeutics."
For more information on SAGE Labs visit www.sageresearchmodels.com. For more information on Ace Animals visit www.aceanimals.com.
Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "is expected to greatly enhance," "plans to offer," "expected to benefit," "premier source," "instrumental" or similar expressions, or by express or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that products will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich brand that represents Sigma's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range of critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.
About SAGE Labs: SAGE Labs, a Sigma Life Science initiative, is a world-class provider of research models, including knockout rat models, and extensive support services. Using Sigma's proprietary platform technologies, SAGE specializes in genetic manipulation of in vivo systems for specialized R&D applications. SAGE Labs specializes in the development and characterization of unique, next-generation animal research models featuring specific gene deletions, insertions, repressions and modifications using proprietary CompoZr ZFN (zinc finger nuclease) technology. This genetic manipulation technology works for a variety of animal research models, as well as a wide range of research applications.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.
CompoZr, SAGEspeed, SAGE, Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.
SOURCE Sigma-Aldrich
Sigma(R) Life Science Introduces World's First Suite of Knockout Rats for ADME/Tox Applications
Date : 03/08/2010 @ 1:00AM
Source : PR Newswire
Stock : Sigma-Aldrich (MM) (SIAL)
Quote : 52.95 1.24 (2.40%) @ 7:22AM
Sigma(R) Life Science Introduces World's First Suite of Knockout Rats for ADME/Tox Applications
ST. LOUIS, March 8 /PRNewswire-FirstCall/ --
Sigma ® Life Science, an innovative brand of Sigma-Aldrich ® , today extended its portfolio of knockout rat models with the announcement of a new suite of models designed to facilitate more predictive absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies. This extension of the Company's product offering, the first ever models created especially for ADME/Tox applications, is expected to help researchers establish the efficacy of drugs more rapidly and with greater accuracy, due to the rat's ability to better model human physiology when compared to mouse models currently used.
The four new models were developed by Sigma Advanced Genetic Engineering (SAGE(TM)) Labs (http://www.sageresearchmodels.com/), a Sigma Life Science initiative, and have single gene deletions to well-established drug transporters: Mdr1a (P-glycoprotein), Mrp1 (Multiple drug resistance-associated protein 1), Mrp2 (Multiple drug resistance-associated protein 2), Pxr (Pregnane X receptor), and Bcrp (Breast cancer resistance protein). The validated Mdr1a knockout model is currently available for purchase, while the other models are expected to be available for purchase later this year.
"Until now, the availability of relevant, genetically modified rats was limited. Knockout mice are readily available, but very challenging to use in ADME/Tox applications due to their size and physiology. We've changed that," commented Dr. Edward Weinstein, director of SAGE Labs. "Our knockout rat models offer a platform that can potentially save millions of dollars in development costs for potential drug candidates by providing a more human-like model, and at the same time significantly decrease time to market for these therapeutics. A rat that is deficient in P-glycopotein (PGP) expression, for example, serves as an improved model over the existing mouse model due to its metabolism and physiology, making it more predictive of how a drug will behave in humans. This is of huge benefit to drug discovery, enabling researchers to go back and address issues much sooner than they can today."
The latest knockout rat models were developed using Sigma-Aldrich's proprietary CompoZr(TM) Zinc Finger Nuclease (ZFN) (http://www.compozrzfn.com/) gene editing technology, which enables scientists to deactivate or "knockout" specific genes that are associated with human disease.
SAGE Labs is the premier resource for genetically modified rodent disease models and markets its exclusive SAGEspeed(TM) Custom Model Development program for the creation of knockout mouse or rat models in as little as five months. The group is also developing their catalog of knockout rat models across a number of research fields, including Neurobiology, Toxicology, Cardiology and Immunology.
For more information on SAGE Labs or to register interest in a specific knockout rat model, visit http://www.sageresearchmodels.com/.
Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "expected to help," "more rapidly," "greater accuracy," "can potentially save millions of dollars," "significantly decrease time to market," "improved model," "huge benefit," "premier source," or similar expressions, or by express or implied discussions regarding knockout rats, or regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that our knockout rat products will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich brand that represents Sigma's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose innovative biology and organic chemistry products are used by scientists around the world, involved in genomic and proteomics, biotechnology research and pharmaceutical development, and in pharmaceutical, diagnostics and other high technology manufacturing. Sigma-Aldrich operates in 38 countries and its 7,800 employees all contribute to providing excellence in service worldwide. For more information about Sigma-Aldrich visit http://www.sigma-aldrich.com/.
CompoZr, SAGEspeed, SAGE, Sigma-Aldrich and Sigma are trademarks or registered trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.
DATASOURCE: Sigma-Aldrich
CONTACT: Sarah Bruno of Sigma-Aldrich, +1-314-286-7810,sarah.bruno@sial.com; or media, Richard Kerns, + 44 (0)161-728-5880,richard@impress-pr.com, or Mark Button, +1-503-616-3817, mark@impress-pr.com,both of Impress Public Relations, for Sigma-Aldrich
Web Site: http://www.sigma-aldrich.com/
Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform
Date : 03/02/2010 @ 1:00AM
Source : PR Newswire
Stock : Sigma-Aldrich (MM) (SIAL)
Quote : 50.59 1.29 (2.62%) @ 3:50PM
Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform
ST. LOUIS, March 2 /PRNewswire-FirstCall/ --
Sigma-Aldrich® today unveiled its new Sigma® Life Science brand and website platform, designed to elevate the Company's current focus on biology and provide a single destination where researchers can access deep biological knowledge and market-leading products and technologies. The introduction of Sigma Life Science's 'Where Bio Begins' brand (http://www.wherebiobegins.com/) brings attention to its biology focus by providing researchers with robust, unique, industry-leading technologies and biologically- focused products to help them explore, study and understand life.
The Sigma Life Science mission is expected to enable researchers to unravel the complex biomolecular interactions within cells, tissues, organs and organisms. The new brand and website are expected to generate awareness of Sigma Life Science's strengths in providing products and technologies that are intended to facilitate scientists' understanding of how diseases develop and how molecules function.
"Our new brand will help us tell our biology story - that Sigma holds what we believe is one of the largest portfolios of biologically rich products and technologies in the industry," said Dr. David Smoller, president of Sigma-Aldrich's Research Biotech business unit. "We have over $750 million worth of products in our portfolio and are fully committed to helping biologists. For over 50 years, life scientists around the world have depended upon our traditional foundation of bioessentials, including biochemicals, amino acids, antibodies, buffers, carbohydrates, enzymes, forensic tools, hematology, histology, nucleotides and cell culture media because of our quality, service and selection. Over the last few years we have built on this strong foundation to develop innovative products and technologies and become a true leader in the life science market." Sigma Life Science is a leading biomolecule provider with:
-- The world's largest custom oligonucleotide service supplying customers around the globe with high quality DNA and RNA and, in many regions, same-day custom DNA synthesis; -- A growing portfolio of more than 25,000 monoclonal and polyclonal antibodies including Prestige Antibodies® Powered by Atlas Antibodies, the industry's most highly-validated antibodies; and -- The largest number of bioactive small molecules, peptides and proteins for cell biology and neuroscience research including GPCR and ion channel ligands, novel kinase inhibitors and cell cycle regulators, the gold-standard LOPAC(TM) library of pharmacologically active compounds and key signal transduction enzymes featuring Precisio(TM) kinases.
Sigma Life Science is also emerging as a leader in innovation with:
-- Cutting-edge gene silencing products, MISSION® siRNAs and the largest set of validated lentivirus based MISSION® shRNA clones; -- The award-winning CompoZr(TM) Zinc Finger Nucleases (ZFN) gene editing technology - the first technology to allow researchers to insert, delete or edit any region of the genome of a living cell or organism; -- SAGE(TM) Labs - the first knockout rat program designed to develop novel rodent models of human disease powered by the CompoZr(TM) ZFN technology; and -- Comprehensive and innovative sets of reagents for regenerative medicine including the Stemgent(TM) reprogramming kit to develop induced pluripotent stem (iPS) cells leveraging the Sigma Life Science lentivirus delivery expertise; HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) to optimize stem cell proliferation and differentiation and a complete portfolio of zinc finger nuclease reagents, antibodies, shRNA/siRNAs for stem cell research.
All of these technologies are accessible through the 'Your Favorite Gene powered by Ingenuity' (http://sigma.com/yfg) search engine - the most dynamic, web-based biological search tool that delivers comprehensive gene-based content to model and evaluate experiments in the context of previously published scientific literature.
"Over the past couple of years we have been working very hard in an attempt to gather the most talented people who are passionate about helping life scientists around the world understand the secrets of life and address the main challenges in biology." said Dr. Helge Bastian, Vice President of Sigma-Aldrich's Research Biotech business unit. "These efforts have transformed our life science business into what we believe is an innovation powerhouse that surprises the market with genuine product innovations. Our award-winning, dynamic web-based biological search tool, 'Your Favorite Gene', our Prestige antibody collection, our ground-breaking CompoZr ZFN technology and the novel, ZFN-enabled knockout rat models generated by our SAGE(TM) Labs business are proof of the things that researchers can expect from Sigma's Life Science business now and in the future: technologies and products that help advance life science and provide deeper insight into biology leading to better medicines and cures. We are committed more than ever to support life science researchers on their way to new discoveries for a healthier and better life. For researchers, Sigma Life Science is the destination where the new biology begins." To support the 'Where Bio Begins' launch, eight information portals have been specifically tailored to serve the biology community. Themed around the Company's core biological capabilities in targeted genome editing (bioediting), transgenics (SAGE Labs), functional genomics (biosilencing), stem cell research and epigenetics (bioreprogramming), molecular biology (biomapping), biomolecules, oligonucleotides/custom products (bionucleics), customer education and training programs (biouniversity) and bioinformatic resource (Your Favorite Gene) these sites can be accessed at http://www.wherebiobegins.com/.
The Sigma Life Science blog at http://sigmabioblogs.com/ serves as a resource for new techniques, improvements to old techniques, exciting applications, and information about scientists from every spectrum of the biological community. We plan to extend our presence via the Where Bio Begins Facebook® Fan page and Where Bio Begins Twitter account at http://twitter.com/WhereBioBegins to engage the biology community. Our existing Social Media presence as SAGE Research Models (http://twitter.com/ResearchModels or the SAGE Research Models Facebook® Fan page), Your Favorite Gene (http://twitter.com/YourFaveGene or the YFG Facebook® Fan ), and CompoZr ZFN Facebook® fan page are intended to communicate with the biocommunity around topics more directly related to using Sigma Life Science tools and techniques.
Cautionary statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "designed to elevate," "is expected to generate," " emerging as a leader in innovation," "most dynamic, web-based biological search tool," or similar expressions, or by express or implied discussions regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Sigma Life Science products will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich brand that represents Sigma's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com/.
Sigma-Aldrich, Sigma, Prestige Antibodies, CompoZr, Precisio, MISSION, SAGE and LOPAC are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co. Stemgent is a trademark of Stemgent, Inc. Hystem is a trademark of Glycosan BioSystems, Inc. Facebook is a registered trademark of Facebook, Inc. DATASOURCE: Sigma-Aldrich CONTACT: Sarah Bruno of Sigma-Aldrich, +1-314-286-7810,sarah.bruno@sial.com; or Media, Laura Hedges of Impress Public Relations, +1-503-616-3857,
Sigma-Aldrich (Nasdaq: SIAL) Reports 12% Year-Over-Year Increase in Q4 2009 Sales; Fourth Quarter 2009 Diluted EPS Up 10% to $0.
http://ih.advfn.com/p.php?pid=nmona&article=41474339&symbol=SIAL
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
I've played around with the ibox a bit...will get it more up to date later this week. ;)
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
That's interesting. ;)
"Be kinder than necessary, for everyone you meet is fighting some kind of battle."
Sigma-Aldrich New Mobile Device Website Puts Scientific Information at the Fingertips of the Research Community
Date : 01/21/2010 @ 8:00AM
Source : PR Newswire
Stock : (SIAL)
Quote : 51.0 -0.48 (-0.93%) @ 7:22AM
Sigma-Aldrich New Mobile Device Website Puts Scientific Information at the Fingertips of the Research Community
ST. LOUIS, Jan. 21 /PRNewswire-FirstCall/ --
Sigma-Aldrich® (NASDAQ:SIAL) announced today the launch of its new mobile device website, designed specifically for access by smart phones and other mobile devices. The site (http://www.sigma-aldrich.com/mobile) brings Sigma-Aldrich's rich scientific content directly to the growing researcher community that prefers to communicate using mobile platforms. The site, optimized for iPhone®, iPod Touch® and Blackberry®, can be accessed by all mobile devices
"The mobile device website is a dynamic tool designed to facilitate scientific collaboration, information sharing and networking within the research community," said Karen Miller, Senior Vice President, Strategy & Corporate Development. "As innovation in web-access for scientific products, services and technologies continues to trend upward, our platforms must support the market with convenient, quick access through this medium, which is second nature to many of our customers. The launch of the mobile device website demonstrates Sigma-Aldrich's commitment to providing researchers the information they need to enable discovery."
Previously, the Company launched the 'What's Your Favorite Gene?' application on the Facebook® Platform to unite scientists around research areas of interest and to enable information sharing and networking
The mobile device website enables visitors to access complete product properties and descriptions for more than 130,000 products, as well as approximately 90,000 technical documents and 200,000 chemical structures and images. In addition, scientists can access Certificates of Analysis, Specification Sheets and other details to ensure quality and safety. Price and availability information for all of the Company's products is also included on the mobile device website, with a convenient e-mail option for collaboration and ordering through the desktop site
To access the new Sigma-Aldrich mobile device website, visit http://sigma-aldrich.com/mobile
The foregoing release contains forward-looking statements that can be identified by terminology such as "optimized," "designed to," "convenient, quick access," "continue to trend upward" or similar expressions, or by express or implied discussions regarding Sigma-Aldrich's mobile device website, or regarding potential future revenues from information derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that information derived from the mobile device website will continue to meet the demands of the marketplace. Nor can there be any guarantee that accessibility to the mobile device website will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these web tools could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com/
Sigma-Aldrich is a registered trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co
IPhone and iPod Touch are trademarks of Apple, Inc. Blackberry is a registered trademark of Research in Motion Limited. Facebook is a registered trademark of Facebook, Inc.
http://www.newscom.com/cgi-bin/prnh/20050215/CGSIGMAALLOGO
http://photoarchive.ap.org/
DATASOURCE: Sigma-Aldrich
CONTACT: Sean Battles of Sigma-Aldrich, +1-314-286-7616,
Web Site: http://www.sigma-aldrich.com/
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
58
|
Created
|
01/16/10
|
Type
|
Free
|
Moderators |
Sigma-Aldrich Corp (Nasdaq: SIAL)
http://www.sigmaaldrich.com/united-states.html
Company Information:
Sigma-Aldrich Corp.
3050 Spruce Street
St. Louis, MO 63103
Phone: 314-771-5765
800-521-8956
CIK: 0000090185
Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing.
Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 40 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology.
Management:
http://investor.sigmaaldrich.com/management.cfm
Top Institutional Holders:
Ownership Profile: http://investor.sigmaaldrich.com/ownership-profile.cfm
Press Releases:
http://investor.sigmaaldrich.com/releases.cfm
http://finance.yahoo.com/q/h?s=SIAL+Headlines
Filings:
Transfer Agent:
Registered Shareholder Contact Information
American Stock Transfer & Trust Company
Shareholder Services Department
6201 15th Street
Brooklyn, NY 11219
Toll Free: (800) 937-5449
Local & International: (718) 921-8124
Email: investors@amstock.com
Web site: http://www.amstock.com
Share Structure:
See SEC filings
Investor Relations:
http://investor.sigmaaldrich.com/
Primary IR Contact
Quintin Lai
Vice President – Investor Relations and Corporate Communications
Email: investorrelations@sial.com
Sigma-Aldrich Corporation
Phone: 314-898-443
Fax: 314-286-7874
" />
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |